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Castleman disease (CD), also referred to as antgiofollicular lymph node hyperplasia, giant cell lymph node hyperplasia, benign giant lymt
phoma, lymphoid hamartoma, was first described by 
Caslteman and Towne in 1954.1,2 CD is a heterogenous 
disorder and may present as a unicentric or multicent
tric type. Pathologically, three distinct varieties, hyaline 
vascular, plasmacytic and mixed, have been recognized.2 
CD is considered a nontclonal disorder, but clonal abt
normalities have been detected in some patients with 
multicentric disease.3
Systemic CD is known to be associated with autot
immune phenomena, including immune thrombocytot
penia.4 Although optimal therapy for CD is not clearly 
defined, steroids have been used in the management 
with a reported response rate of 60%. The responses are 
shorttlived, however.5,6
Recently several reports have appeared in support 
of the use of antitCD20 antibody (rituximab) in the 
treatment of immune thrombocytopenia7t10 as well as 
in multicentric CD.11t13 However, there are no reports 
of antitCD20 therapy in immune thrombocytopenia 
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multicentric Castleman disease (mCD) is a lymphoproliferative disorder of incompletely understood 
etiology and with various clinical presentations. the best therapeutic option for this disease is not well 
established. mCD is known to be associated with autoimmune phenomena. a 70-year-old female patient 
of mCD with progressive nodal disease associated with autoimmune thrombocytopenia failed steroid 
treatment and showed a transient response to intravenous immunoglobulin. the patient achieved com-
plete recovery of her platelet count and a very good response in nodal disease after 3 weekly doses of 
anti-CD-20 antibody (rituximab). anti-CD20 antibody treatment could be a good therapeutic option for 
mCD, mainly when associated with immune-related disorders. 
associated with CD. We report on a patient with mixed 
variant of multicentric Castleman disease associated 
with immune thrombocytopenia successfully treated 
with rituximab. 
CASE
A 70tyeartold female presented with a 2tmonth history 
of bilateral neck and right axillary swelling at a private 
institution. A lymph node biopsy was suggestive of lymt
phoma and she was referred to our hospital for further 
care. Her pathology review documented the presence of 
mixedtvariant Castleman disease (Figure 1). Staging 
worktup revealed bilateral cervical and right axillary 
lymphadenopathy. Her peripheral blood counts revealed 
a normal white blood cell count of 9.02×109/L, normal 
hemoglobin of 128 g/L and low platelets of 28×109/
L. She was managed expectantly despite evidence of 
lymph node enlargement. In September 2009, she pret
sented with significant progression of her adenopathy 
and marked thrombocytopenia (2.0×109/L). Staging 
worktup revealed the presence of enlarged lymph nodes 
in the neck, axillae, mediastinum, abdomen and pelvis, 
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in addition to pleural effusions. A bone marrow aspirat
tion revealed no evidence of tumor or infection in the 
marrow and an increased number of megakaryocytes. 
She was admitted with a diagnosis of progressive mult
ticentric Castleman disease and immune thrombocyt
topenia. She was started on prednisone at the dose of 
1mg/kg without improvement and was then given int
travenous immune globulin at the dose of 1g/kg for two 
consecutive days. After an initial rise in platelet count, 
it decreased again to 17×109/L within 7 days (Figure 
2). The patient was then started on rituximab 375 mg/
m2/week for 4 weeks. The platelet count recovered to 
142×109/L after three doses and there was dramatic ret
sponse with complete clinical disappearance of cervical 
and axillary adenopathy. The patient was discharged in 
stable condition and 6 months after rituximab therapy, 
had a stable platelet count and no evidence of progrest
sion of lymphadenopathy. 
DISCUSSION
The rarity and heterogeneity of CD have precluded 
properly designed trials of treatment and the majort
ity of treatment recommendations are based on case 
reports, or case series. Unicentric CD, whether hyat
line vascular or plasmacytic, is generally treated with 
surgical excision. When surgery is not feasible, irrat
diation may be considered and either treatment may 
be curative. Observation alone may be a valid option 
in some cases. Multicentric disease is rarely asympt
tomatic and surgical excision alone is rarely curative. 
These patients frequently require systemic therapy.14 
A number of therapies have been used for multicentric 
disease, including intravenous immunoglobulin, antit
herpes drugs, e.g. aciclovir, (val) ganciclovir in HIV+ 
and HHV8+ disease, combination chemotherapy (e.g., 
CHOP) and in intractable cases even autologous stem 
cell transplantation. Other therapies include the antit
angiogenesis therapy, thalidomide and antitIL6 therapy. 
Surgery may also be useful in debulking disease. Our 
patient remained asymptomatic for more than one year 
and therefore, was managed expectantly. The first indit
cation of symptomatic disease was presentation with 
severe thrombocytopenia. 
 Therapy with hightdose corticosteroids is the maint
stay of treatment for primary ITP. Hightdose corticot
steroids may also reduce bleeding by a direct effect on 
blood vessels, independent of platelet rise.15t18 In addit
tion, steroids have been used for symptomatic relief in 
CD with reduction in lymph node size, improvement 
of symptoms, and correction of blood count abnormalit
ties.5,6 The benefit is transient and symptoms usually 
recur soon upon discontinuation. Our patient did not 
respond to adequate doses of steroids and responded 
only transiently to IVIG. 
Several studies have reported a response rate of up 
to 60% with antitCD20 antibody therapy with comt
plete remissions approaching 40% in chronic ITP.7t10 
These responses generally begin from 1 to 8 weeks aft
ter initiating antitCD20 therapy19,20 and may last from 
2 months in partial responders to 5 years or longer in 
Figure 1. (A) Low power shows lymph node replaced by follicles with broad mantle 
zones (‘onion skinning’) and hyalinized blood vessels. H&E ×200. (B) A follicle with few 
scattered follicle-center cells and many large atypical follicular dendritic cells. H&E 
×400. (C) Immunoperoxidase staining for CD21 demonstrating increased number of 
follicular dendritic cells and relative lack of follicle-center cells. ×400. (D)Large number 
of plasma cells present within the interfollicular region - polyclonal by light chain 
immunoperoxidase staining: Kappa (a) and lambda (b). ×400
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Figure 2. Platelet response to therapy.
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15% to 20% of those who achieve complete remission.7 
Recent reports also suggest that rituximab may be an 
attractive option in systemic Castleman disease since 
follicular areas strongly express CD20 in MCD. Most 
of these are, however, associated with HIV+/HHVt
8+.11t13 Our patient tested negative for both HIV and 
HHVt8. To our knowledge, this is the first reported 
case where rituximab was tried in ITP associated with 
CD and both ITP and primary disease, i.e., Castleman 
disease showed good response. 
In conclusion, antitCD20 antibody therapy may be 
an attractive therapeutic option for Castleman disease, 
especially if associated with immune cytopenias, even in 
the absence of HIV or HHVt8. 
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